Резолюция Экспертного совета «Диагностика и лечение больных со сладжем в желчном пузыре»

Aim of publication. To present the data of Advisory council which took place on August 19, 2016 in Poland (Krakow) with the participation of Adamed Russia company. Summary. Advisory council activity provided the algorithm of diagnosis and treatment of biliary sludge. At detection of gallbladder sludge in a patient with right hypochondrial pain it is necessary to carry out general examination to rule out the other diseases that may be dangerous (neoplastic, acute cholecystitis, pancreatitis). In the absence of other changes, besides biliary sludge, prescription of initial course of hymecromone combined to ursodeoxycholic acid (UDCA) is indicated. In the case of clinical improvement at primary therapy course it is necessary to continue UDCA treatment for 3 months. Primary treatment course that should include combination of hymecromone and UDCA is indicated for those patients with asymptomatic sludge, who have putty-like bile in the gallbladder or bile ducts. In the case over the other forms of asymptomatic sludge usually only diet limitations and follow up (abdominal US every six months) are indicated. At detection of the ultrasound signs, typical for chronic pancreatitis, according to the Cambridge diagnostic criteria, verification of the diagnosis by multidetector computer tomography according to the pancreatic protocol is mandatory. Selective antispasmodic medications (e.g. hymecromone) will be one of the basic pharmaceutical agents in this case, indications to endoscopic treatment should be evaluated, typically - by means of endoscopic ultrasound investigation). Conclusions. At of patient with the biliary sludge selective antispasmodic medications and UDCA should be widely applied, in some cases methods of endoscopic surgery as well.

1. Cotton P.B., Elta G.H., Carter C.R., Pasricha P.J., Corazziari E.S. Rome IV. Gallbladder and Sphincter of Oddi Disorders. Gastroenterology 2016.

2. Goussous N., Kowdley G.C., Sardana N., Spiegler E., Cunningham S.C. Gallbladder dysfunction: how much longer will it be controversial? Digestion 2014;90(3):14754.

3. Cotton P. B., Durkalski V., Romagnuolo J., Pauls Q., Fogel E., Tarnasky P. et al. Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial. JAMA 2014;311(20):2101-9.

4. Tarnasky P.R., Hoffman B., Aabakken L., Knapple W.L., Coyle W., Pineau B. et al. Sphincter of Oddi dysfunction is associated with chronic pancreatitis. Am J Gastroenterol 1997;92(7):1125-9.

5. Devereaux B.M., Sherman S., Lehman G.A. Sphincter of Oddi (pancreatic) hypertension and recurrent pancreatitis. Curr Gastroenterol Reports 2002;4(2):153-9.

6. Nagy N., Kuipers H.F., Frymoyer A.R., Ishak H.D., Bollyky J.B., Wight T.N. et al. 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol 2015;6:123.

7. Abate A., Dimartino V., Spina P., Costa P.L., Lombardo C., Santini A. et al. Hymecromone in the treatment of motor disorders of the bile ducts: a multicenter, double-blind, placebo-controlled clinical study. Drugs Under Exp Clin Res 2001; 27(5-6):223-31.

8. Garrett E.R., Venitz J. Comparisons of detections, stabilities, and kinetics of degradation of hymecromone and its glucuronide and sulfate metabolites. J Pharm Sci 1994;83(1):115-6.

9. Takeda S., Aburada M. The choleretic mechanism of coumarin compounds and phenolic compounds. J Pharmacobio-dynamics 1981;4(9):724-34.

10. Tanayama S., Kanai Y. Studies on increased bile formation produced by polyoxybenzenes in rats. Jap J Pharmacol 1977;27(1):71-8.

11. Trabucchi E., Baratti C., Centemero A., Zuin M., Rizzitelli E., Colombo R. Controlled study of the effects of tiropramide on biliary dyskinesia. Pharmatherapeutica 1986;4(9):541-50.

12. Stacchino C., Spano R., Pettiti A. Spasmolytic activity of some 4-methylumbelliferone derivatives. Bollettino Chim Farma 1983;122(3):158-60.

13. Godfraind T., Lesne M. The uptake of cardiac glycosides by intestinal smooth muscle of the guinea-pig in relation to digitalis receptors. Br J Pharmacol 1970;38(2):345-52.

14. Leal L.K., Nechio M., Silveira E.R., Canuto K.M., Fontenele J.B., Ribeiro R.A. et al. Anti-inflammatory and smooth muscle relaxant activities of the hydroalcoholic extract and chemical constituents from Amburana cearensis A C Smith. Phytother Res 2003;17(4):335-40.

15. Hoult J.R., Paya M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen Pharmacol 1996; 27(4):713-22.

16. Najmanova I., Dosedel M., Hrdina R., Anzenbacher P., Filipsky T., Riha M. et al. Cardiovascular effects of coumarins besides their antioxidant activity. Curr Top Med Chem 2015; 15(9):830-49.

17. Hoffmann R.M., Schwarz G., Pohl C., Ziegenhagen D.J., Kruis W. [Bile acid-independent effect of hymecromone on bile secretion and common bile duct motility]. Dtsch Med Wschr 2005;130(34-35):1938-43.

18. Venu R.P., Geenen J.E., Hogan W., Stone J., Johnson G.K., Soergel K. Idiopathic recurrent pancreatitis. An approach to diagnosis and treatment. Dig Dis Sci 1989; 34(1):56-60.

19. Lee S.P., Nicholls J.F., Park H.Z. Biliary sludge as a cause of acute pancreatitis. N Eng J Med 1992;326(9):58993.

20. Ros E., Navarro S., Bru C., Garcia-Puges A., Valderrama R. Occult microlithiasis in ‘idiopathic’ acute pancreatitis: prevention of relapses by cholecystectomy or ursodeoxycholic acid therapy. Gastroenterology 1991; 101(6):1701-9.

21. Okazaki K., Yamamoto Y., Nishimori I., Nishioka T., Kagiyama S., Tamura S. et al. Motility of the sphincter of Oddi and pancreatic main ductal pressure in patients with alcoholic, gallstone-associated, and idiopathic chronic pancreatitis. Am J Gastroenterol 1988; 83(8):820-6.

22. Lee Y.S., Kang B.K., Hwang I.K., Kim J., Hwang J.H. Long-term Outcomes of Symptomatic Gallbladder Sludge. J Clin Gastroenterol 2015; 49(7):594-8.

23. Насонова С.В., Цветкова Л.И. Опыт применения Одестона в лечении хронических заболеваний желчного пузыря и желчевыводящих путей. Рос журн гастроэнтерол гепатол колопроктол 2000; (3):87-90.